

**South East London Integrated Medicines Optimisation Committee
(SEL IMOC)**

**Withdrawal of position statement 001
(issued March 2015):**

**Biosimilar infliximab (CT-P13) - manufactured by Celltrion and marketed in
the UK as Inflectra® (Hospira) or Remsima® (Napp)**

As the arrangements for considering biosimilars locally have evolved since this position statement was originally issued, the Committee have agreed to withdraw this statement from local use.

The local SEL specialist pathways for inflammatory bowel disease (IBD), dermatology and rheumatology can be accessed [here](#).

The SEL Formulary can be accessed [here](#)

October 2024